Assertio Therapeutics Inc Capital Reinvestment Ratio
Assertio Therapeutics Inc capital reinvestment ratio. Assertio Therapeutics Inc (ASRT) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($5.71 Million) in capital expenditures ($180.00K). Check ASRT cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Assertio Therapeutics Inc (2005–2023)
Capital reinvestment ratio of Assertio Therapeutics Inc from 2005 to 2023. This chart tracks Assertio Therapeutics Inc's Capital Reinvestment Ratio across 14 annual periods. Also explore Assertio Therapeutics Inc (ASRT) net asset momentum to track the company's year-over-year net asset growth rate.
Assertio Therapeutics Inc Capital Reinvestment Ratio by Year (2005–2023)
Assertio Therapeutics Inc capital reinvestment ratio by year from 2005 to 2023. For the full cash flow conversion analysis, see cash flow conversion of Assertio Therapeutics Inc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.01x | $49.60 Million | $628.00K | ▲ +263.2% |
| 2022 | 0.00x | $78.60 Million | $274.00K | ▼ -63.7% |
| 2021 | 0.01x | $5.52 Million | $53.00K | ▼ -41.4% |
| 2019 | 0.02x | $90.47 Million | $1.48 Million | ▼ -78.5% |
| 2018 | 0.08x | $72.50 Million | $5.51 Million | ▲ +609.1% |
| 2017 | 0.01x | $62.17 Million | $666.00K | ▼ -75.5% |
| 2016 | 0.04x | $65.50 Million | $2.86 Million | ▼ -76.5% |
| 2015 | 0.19x | $143.89 Million | $26.71 Million | ▼ -7.7% |
| 2013 | 0.20x | $9.75 Million | $1.96 Million | ▲ +1561.4% |
| 2011 | 0.01x | $57.65 Million | $698.00K | ▼ -96.5% |
| 2009 | 0.34x | $1.84 Million | $629.00K | ▲ +346.2% |
| 2008 | 0.08x | $3.35 Million | $257.00K | ▲ +620.8% |
| 2007 | 0.01x | $14.66 Million | $156.00K | ▼ -61.2% |
| 2005 | 0.03x | $28.82 Million | $791.25K | — |